Physicians who specialize in obesity said GLP-1 medications are not reaching people in racial and ethnic groups disproportionately affected by the condition, including Black and Latino Americans. The primary obstacles are the drugs’ high cost and limited insurance coverage, which makes them inaccessible to many individuals, especially those from lower-income backgrounds.
A study published Jan. 29 in Plos One found Black patients with diabetes were half as likely to get GLP-1s than white patients in some areas of the U.S.
“If everybody had equal access, then this would be a way to help,” Rocio Pereira, MD, chief of endocrinology at Denver Health, told the Times. “But without equal access — which is what we have now — it’s likely this is going to increase the disparity we see.”
Experts said there is an urgent need to address these disparities and ensure equitable access to obesity treatments for all Americans.
Read the full article here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
